GHRF/growth hormone-releasing factor

Examorelin (Hexarelin) is a synthetic growth hormone-releasing peptide that exerts cardioprotective effects. Regulation of autophagy is known to be cardioprotective so this study examined the role of autophagy and potential regulatory mechanisms in hexarelin-elicited anti-cardiac hypertrophic action in cardiomyocytes subjected to hypertrophy. H9C2 cardiomyocytes were subjected to hypertrophy by angiotensin-II (Ang-II). Autophagic light chain-3 (LC3) and cytoskeletal proteins were determined by immunofluorescence assay. Autophagy was also detected using monodansylcadaverine (MDC) for autophagic vacuole visualization and Cyto-ID staining for autophagic flux measurement. Molecular changes were analysed by Western blotting and qRT-PCR. Apoptosis was evaluated using flow cytometry and TUNEL assay. ATP content and CCK-8 assay were used in assessing enhanced cell survival whilst oxidative stress was analysed by measuring malondialdehyde(MDA) and superoxide dismutase(SOD) levels. Ang-II induced cardiomyocyte hypertrophy, oxidative stress, apoptosis and decreased cell survival, all of which were significantly suppressed by Examorelin (Hexarelin) treatment which also enhanced autophagy in hypertrophic H9C2 cells. Furthermore, inhibition of hexarelin induced autophagy by 3-methyladenine (3MA) abolished the anti-hypertrophic function of hexarelin and also abrogated the protection of hexarelin against cell survival inhibition and apoptosis. Conversely, the application of autophagy stimulator rapamycin in H9C2 hypertrophic cells inhibited apoptosis, cell survival and reduced cell size as well. Additionally, hexarelin regulated the upstream signalling of autophagy by inhibiting the phosphorylation of mammalian target of rapamycin(mTOR). We propose that hexarelin plays a novel role of attenuating cardiomyocyte hypertrophy and apoptosis via an autophagy-dependent mechanism associated with the suppression of the mTOR signalling pathway.

Acute myocardial ischemia and reperfusion injury (IRI) underly the detrimental effects of coronary heart disease on the myocardium. Despite the ongoing advances in reperfusion therapies, there remains a lack of effective therapeutic strategies for preventing IRI. Growth hormone secretagogues (GHS) have been demonstrated to improve cardiac function, attenuate inflammation and modulate the autonomic nervous system (ANS) in models of cardiovascular disease. Recently, we demonstrated a reduction in infarct size after administration of Examorelin (Hexarelin)/HEX, in a murine model of myocardial infarction. In the present study we employed a reperfused ischemic (IR) model, to determine whether HEX would continue to have a cardioprotective influence in a model of higher clinical relevance. Myocardial ischemia was induced by transient ligation of the left descending coronary artery (tLAD) in C57BL/6 J mice followed by HEX (0.3 mg/kg/day; n = 20) or vehicle (VEH) (n = 18) administration for 21 days, first administered immediately prior-to reperfusion. IR-injured and sham mice were subjected to high-field magnetic resonance imaging to assess left ventricular (LV) function, with HEX-treated mice demonstrating a significant improvement in LV function compared with VEH-treated mice. A significant decrease in interstitial collagen, TGF-β1 expression and myofibroblast differentiation was also seen in the HEX-treated mice after 21 days. HEX treatment shifted the ANS balance towards a parasympathetic predominance; combined with a significant decrease in cardiac troponin-I and TNF-α levels, these findings were suggestive of an anti-inflammatory action on the myocardium mediated via HEX. In this model of IR, HEX appeared to rebalance the deregulated ANS and activate vagal anti-inflammatory pathways to prevent adverse remodelling and LV dysfunction. There are limited interventions focusing on IRI that have been successful in improving clinical outcome in acute myocardial infarction (AMI) patients, this study provides compelling evidence towards the translational potential of HEX where all others have largely failed [2].

---

Both Examorelin (Hexarelin) and its natural analog ghrelin exert comparable cardioprotective activities. A single dose of ghrelin administered at the very acute phase after experimental myocardial infarction positively affects cardiac function in chronic heart failure. Therefore, this study aimed to determine whether a single dose of oral Examorelin (Hexarelin) has the same effect in the chronic disease phase. Myocardial infarction or sham operation was generated by left coronary artery ligation in male C57BL/6J mice, which subsequently received one dose of hexarelin or vehicle treatment by oral gavage 30 min after operation. Although the mortality within 14 days after myocardial infarction did not differ between the groups, hexarelin treatment protected cardiac function in the chronic phase as evidenced by higher ejection fraction and fractional shortening, as well as lower lung weight/body weight and lung weight/tibial length ratios, compared with vehicle treatment. Hexarelin treatment concurrently lowered plasma epinephrine and dopamine levels, and shifted the balance of autonomic nervous activity toward parasympathetic nervous activity as evidenced by a smaller low/high-frequency power ratio and larger normalized high-frequency power on heart rate variability analysis. The results first demonstrate that one dose of oral hexarelin treatment potentially protects chronic cardiac function after acute myocardial infarction, and implicate that activating growth hormone secretagogue receptor 1a might be beneficial for cardioprotection, although other mechanism may also be involved[3].

Cytokine and Cardiac troponin (CnT)-I determination [2]
Blood samples were collected 24 h and 21 days post tLAD ligation or sham procedure. The blood was allowed to clot and samples were centrifuged. The serum was immediately removed and stored at −80 °C until assayed. The serum concentrations of CnT-I, interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α were measured at 24 h and 21 days post-operatively using a MILLIPLEX® map Assay according to the manufacturer’s instructions.

---

HRV analysis [2]
HRV analysis was performed 21 days post tLAD ligation or sham procedure. ECG signals were recorded using a physiological analyzing system. Mice were anaesthetized with isoflurane and ECG signals were recorded for a minimum of 20 min once the heart rate (HR) had stabilized. ANS function was examined by power spectral analysis of HRV where HR was used to generate a power spectral density curve using a fast Fourier transformation.

Treatment administration [2]
Examorelin (Hexarelin)(0.3 mg/kg/day) or VEH was administered SC to each mouse immediately prior to reperfusion. Similarly, mice undergoing the sham procedure also received either VEH or Examorelin (Hexarelin) treatment. This dose was chosen based on previous studies demonstrating a cardioprotective effect. All mice then received their respective treatments once daily throughout the 21-day study period.

---

Examorelin (Hexarelin) and vehicle administration [3]
Examorelin (Hexarelin) (600 μg per mouse) or vehicle was administered to 24 mice each by oral gavage 30 min after the MI procedure (hexarelin- or vehicle-treated group), and 10 mice after sham operation were also received oral vehicle administration (sham-operated group). The dose of oral hexarelin was chosen to be as effective as 40 μg/kg subcutaneous administration, which is approximately equimolar with that of ghrelin in the previous study.

[1]. Hexarelin protects cardiac H9C2 cells from angiotensin II-induced hypertrophy via the regulation of autophagy. Pharmazie. 2019 Aug 1;74(8):485-491.
[2]. Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion. Biomed Pharmacother. 2020 Jul:127:110165.
[3]. One dose of oral hexarelin protects chronic cardiac function after myocardial infarction. Peptides. 2014 Jun;56:156-62.

Conclusion: Targeting autonomic imbalance by augmentation of parasympathetic tone has emerged as a promising therapeutic approach for management of ischemic heart disease and H. The VN is suggested to play a central role in GHS-observed effects and acts as an endogenous mechanism to regulate the immune response and inflammation. In the present study, Examorelin (Hexarelin) treatment was demonstrated to modulate the ANS and influence the inflammatory response induced by myocardial IR. Our results demonstrate that Examorelin (Hexarelin) may have an important influence on balancing the sympathetic and parasympathetic nervous system and modulating adverse inflammatory pathways in response to AMI. Pharmacological stimulation of the VN by Examorelin (Hexarelin) may offer a novel cardioprotective strategy against IRI by preventing myofibroblast activation and LV remodelling in AMI.[2]
Clinical relevance: The research field of cardio-protection has been plagued by numerous failed attempts to translate promising therapeutic strategies for preventing myocardial ischemic injury discovered in the basic science laboratory into the clinical setting. A major factor underlying this failure entails the inappropriate use of experimental animal models. In our previous study we were able to clearly demonstrate the cardioprotective effect of Examorelin (Hexarelin) therapy in a mouse model of permanent MI, however, the translational aspect of this model is limited. Examorelin (Hexarelin) as an emerging therapeutic agent for prevention of myocardial IRI has shown promise in this study using a clinically relevant model, where Examorelin (Hexarelin) was administered prior to myocardial reperfusion (removal of the coronary ligature), representing a protocol that could be employed in the reperfusion unit. Therefore, this study signifies a noteworthy contribution to the field of cardio-protection.

---

In conclusion, one dose of oral Examorelin (Hexarelin) in the very acute phase after MI can protect cardiac function in the chronic phase despite a lack of improvement in total mortality. In addition, it can lower plasma epinephrine and dopamine levels, and shift the autonomic nervous activity balance toward parasympathetic nervous activity. This study is the first to provide clear evidence supporting oral Examorelin (Hexarelin) as a potential treatment for acute MI to protect chronic cardiac function. [3]

C47H58N12O6

887.040220000001

886.46

C, 63.64; H, 6.59; N, 18.95; O, 10.82

140703-51-1

6918297

H-His-D-Trp(2-Me)-Ala-Trp-D-Phe-Lys-NH2; L-histidyl-2-methyl-D-tryptophyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide

HXAWFK

Typically exists as solid at room temperature

1.322 g/cm3

1403.6ºC at 760 mmHg

802.7ºC

0mmHg at 25°C

1.66

5.392

11

9

23

65

1600

6

CC1=C(C2=CC=CC=C2N1)C[C@@H](NC([C@@H](N)CC3=CN=CN3)=O)C(N[C@H](C(N[C@H](C(N[C@@H](C(N[C@H](C(N)=O)CCCCN)=O)CC4=CC=CC=C4)=O)CC5=CNC6=CC=CC=C56)=O)C)=O

RVWNMGKSNGWLOL-GIIHNPQRSA-N

InChI=1S/C47H58N12O6/c1-27-34(33-15-7-9-17-37(33)54-27)23-41(58-44(62)35(49)22-31-25-51-26-53-31)45(63)55-28(2)43(61)57-40(21-30-24-52-36-16-8-6-14-32(30)36)47(65)59-39(20-29-12-4-3-5-13-29)46(64)56-38(42(50)60)18-10-11-19-48/h3-9,12-17,24-26,28,35,38-41,52,54H,10-11,18-23,48-49H2,1-2H3,(H2,50,60)(H,51,53)(H,55,63)(H,56,64)(H,57,61)(H,58,62)(H,59,65)/t28-,35-,38-,39+,40-,41+/m0/s1

L-Lysinamide, L-histidyl-2-methyl-D-tryptophyl-L-alanyl-L-tryptophyl-D-phenylalanyl-

EP-23905; MF-6003; EP23905; Hexarelin; Examorelin; 140703-51-1; Examorelin [INN]; examorelina; examoreline; L-Lysinamide, L-histidyl-2-methyl-D-tryptophyl-L-alanyl-L-tryptophyl-D-phenylalanyl-; EP-23,905; MF6003; EP 23905; MF 6003

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

---

Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).

View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)

---

Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).

View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

---

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

---

 (Please use freshly prepared in vivo formulations for optimal results.)